GLP-1s in general are typically recommended and usually only covered by insurance for people with obesity (defined as a BMI greater than 30) as well as those with a BMI greater than 27 and one or more weight-related conditions such as high blood pressure, type 2 diabetes, or high cholesterol
She's named on the brand's landing page alongside a photo and title, but no independent public record - a licensing database, a published research affiliation, or a company staff listing outside the brand's own marketing - was located to confirm her identity or credentials during this review
Frequently Asked Questions How quickly will I regain weight after stopping semaglutide
The reality check: longer trials did not justify a commercial obesity drug The same obesity-pharmacotherapy review literature notes that development was terminated after a longer trial failed to demonstrate sufficiently meaningful weight loss to be commercially viable
In gastric cancer, increased infiltration of CD20+ B cells in gastric cancer tissues, as detected by immunohistochemistry, is associated with improved patient outcomes (142)
Kessler, H
